{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:56:23Z","timestamp":1790283383482,"version":"4.1.0"},"reference-count":26,"publisher":"Archives of Endocrinology and Metabolism","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"DOI":"10.20945\/2359-4292-2023-0503","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T17:11:43Z","timestamp":1729530703000},"source":"Crossref","is-referenced-by-count":3,"title":["Metabolic impact of residual C-peptide secretion in type 1 diabetes mellitus"],"prefix":"10.20945","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-7709","authenticated-orcid":false,"given":"Valentim","family":"Lopes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1752-2685","authenticated-orcid":false,"given":"Maria Eduarda","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3888-5938","authenticated-orcid":false,"given":"Sara Campos","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0499-9790","authenticated-orcid":false,"given":"Adriana De Sousa","family":"Lages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8510","reference":[{"key":"key20241021171135_B1","author":"IDF","year":"2021","unstructured":"1. IDF. IDF Diabetes Atlas 10th edition. 2021. Available from: www.diabetesatlas.org. Access on: Mar 2024.","journal-title":"IDF Diabetes Atlas 10th edition"},{"issue":"1","key":"key20241021171135_B2","first-page":"19","article-title":"Diabetes: Factos e N\u00fameros 2016, 2017 e 2018","volume":"15","author":"Raposo","year":"2020","unstructured":"2. Raposo JF. Diabetes: Factos e N\u00fameros 2016, 2017 e 2018. Rev Port Diabetes. 2020;15(1):19-27.","journal-title":"Rev Port Diabetes"},{"issue":"1","key":"key20241021171135_B3","first-page":"1","article-title":"Classification of diabetes mellitus","volume":"21","author":"Kazi","year":"2001","unstructured":"3. Kazi AA, Blonde L. Classification of diabetes mellitus. Clin Lab Med. 2001;21(1):1-13.","journal-title":"Clin Lab Med"},{"issue":"1","key":"key20241021171135_B4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08916930701619169","article-title":"Autoantibodies in type 1 diabetes","volume":"41","author":"Taplin","year":"2008","unstructured":"4. Taplin C, Barker J. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41(1):11-8. doi: 10.1080\/08916930701619169.","journal-title":"Autoimmunity"},{"key":"key20241021171135_B5","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"5. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15-S33. doi: 10.2337\/dc21-S002.","journal-title":"Diabetes Care"},{"key":"key20241021171135_B6","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","unstructured":"6. Katsarou A, Gudbj\u00f6rnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, et al. Type 1 diabetes mellitus. Nat Rev Dis Primers. 2017;3:17016. doi: 10.1038\/nrdp.2017.16.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"key20241021171135_B7","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/dme.12850","article-title":"Low levels of C-peptide have clinical significance for established Type 1 diabetes","volume":"32","author":"Kuhtreiber","year":"2015","unstructured":"7. Kuhtreiber WM, Washer SLL, Hsu E, Zhao M, Reinhold P 3rd, Burger D, et al. Low levels of C-peptide have clinical significance for established Type 1 diabetes. Diabet Med. 2015;32(10):1346-53. doi: 10.1111\/dme.12850.","journal-title":"Diabet Med"},{"issue":"7","key":"key20241021171135_B8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","unstructured":"8. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-17. doi: 10.1111\/dme.12159.","journal-title":"Diabet Med"},{"issue":"3","key":"key20241021171135_B9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2337\/dc14-1952","article-title":"Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes","volume":"38","author":"Davis","year":"2015","unstructured":"9. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 2015;38(3):476-81. doi: 10.2337\/dc14-1952.","journal-title":"Diabetes Care"},{"issue":"7","key":"key20241021171135_B10","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc18-0465","article-title":"C-peptide decline in type 1 diabetes has two phases: An initial exponential fall and a subsequent stable phase","volume":"41","author":"Shields","year":"2018","unstructured":"10. Shields BM, McDonald TJ, Oram R, Hill A, Hudson M, Leete P, et al. C-peptide decline in type 1 diabetes has two phases: An initial exponential fall and a subsequent stable phase. Diabetes Care. 2018;41(7):1486-92. doi: 10.2337\/dc18-0465.","journal-title":"Diabetes Care"},{"issue":"3","key":"key20241021171135_B11","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diacare.26.3.832","article-title":"?eta-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial","volume":"26","author":"Steffes","year":"2003","unstructured":"11. Steffes MW, Sibley S, Jackson M, Thomas W. ?eta-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26(3):832-6. doi: 10.2337\/diacare.26.3.832.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241021171135_B12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002288","article-title":"Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes","volume":"9","author":"Wellens","year":"2021","unstructured":"12. Wellens MJ, Vollenbrock CE, Dekker P, Boesten LSM, Geelhoed-Duijvestijn PH, de Vries-Velraeds MMC, et al. Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes. BMJ Open Diabetes Res Care. 2021;9(1):e002288. doi: 10.1136\/bmjdrc-2021-002288.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"key20241021171135_B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00125-020-05099-3","article-title":"Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes","volume":"63","author":"Gibb","year":"2020","unstructured":"13. Gibb FW, McKnight JA, Clarke C, Strachan MWJ. Preserved C-peptide secretion is associated with fewer low-glucose events and lower glucose variability on flash glucose monitoring in adults with type 1 diabetes. Diabetologia. 2020;63(5):906-14. doi: 10.1007\/s00125-020-05099-3.","journal-title":"Diabetologia"},{"issue":"11","key":"key20241021171135_B14","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.2337\/db10-0676","article-title":"Residual insulin production and pancreatic \u00df-cell turnover after 50 years of diabetes: Joslin Medalist Study","volume":"59","author":"Keenan","year":"2010","unstructured":"14. Keenan HA, Sun JK, Levine J, Doria A, Aiello LP, Eisenbarth G, et al. Residual insulin production and pancreatic \u00df-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes. 2010;59(11):2846-53. doi: 10.2337\/db10-0676.","journal-title":"Diabetes"},{"issue":"11","key":"key20241021171135_B15","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1007\/s00125-005-1960-7","article-title":"Latent autoimmune diabetes in adults (LADA) should be less latent","volume":"48","author":"Fourlanos","year":"2005","unstructured":"15. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG, et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia. 2005;48(11):2206-12. doi: 10.1007\/s00125-005-1960-7.","journal-title":"Diabetologia"},{"issue":"2","key":"key20241021171135_B16","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2337\/diacare.26.2.536","article-title":"What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes","volume":"26","author":"Palmer","year":"2003","unstructured":"16. Palmer JP, Hirsch IB. What's in a name: Latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care. 2003;26(2):536-8. doi: 10.2337\/diacare.26.2.536.","journal-title":"Diabetes Care"},{"issue":"1","key":"key20241021171135_B17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00125-013-3067-x","article-title":"The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells","volume":"57","author":"Oram","year":"2014","unstructured":"17. Oram RA, Jones AG, Besser RE, Knight BA, Shields BM, Brown RJ, et al. The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia. 2014;57(1):187-91. doi: 10.1007\/s00125-013-3067-x.","journal-title":"Diabetologia"},{"issue":"2","key":"key20241021171135_B18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/pedi.12135","article-title":"Residual C-peptide in type 1 diabetes: What do we really know?","volume":"15","author":"VanBuecken","year":"2014","unstructured":"18. VanBuecken DE, Greenbaum CJ. Residual C-peptide in type 1 diabetes: What do we really know? Pediatr Diabetes. 2014;15(2):84-90. doi: 10.1111\/pedi.12135.","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"key20241021171135_B19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/diagnostics3040385","article-title":"Continuous Glucose Monitoring Systems: A Review","volume":"3","author":"Vashist","year":"2013","unstructured":"19. Vashist SK. Continuous Glucose Monitoring Systems: A Review. Diagnostics (Basel). 2013;3(4):385-412. doi: 10.3390\/diagnostics3040385.","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"key20241021171135_B20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2337\/dc08-1241","article-title":"Fasting plasma c-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients","volume":"32","author":"Panero","year":"2009","unstructured":"20. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, et al. Fasting plasma c-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care. 2009;32(2):301-5. doi: 10.2337\/dc08-1241.","journal-title":"Diabetes Care"},{"issue":"3","key":"key20241021171135_B21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1464-5491.2000.00274.x","article-title":"Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus","volume":"17","author":"Johansson","year":"2000","unstructured":"21. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med. 2000;17(3):181-9. doi: 10.1046\/j.1464-5491.2000.00274.x.","journal-title":"Diabet Med"},{"issue":"6","key":"key20241021171135_B22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00125-015-3559-y","article-title":"CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes","volume":"58","author":"Buckingham","year":"2015","unstructured":"22. Buckingham B, Cheng P, Beck RW, Kollman C, Ruedy KJ, Weinzimer SA, et al. CGM-measured glucose values have a strong correlation with C-peptide, HbA1c and IDAAC, but do poorly in predicting C-peptide levels in the two years following onset of diabetes. Diabetologia. 2015;58(6):1167-74. doi: 10.1007\/s00125-015-3559-y.","journal-title":"Diabetologia"},{"issue":"7","key":"key20241021171135_B23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/dme.12159","article-title":"The clinical utility of C-peptide measurement in the care of patients with diabetes","volume":"30","author":"Jones","year":"2013","unstructured":"23. Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013;30(7):803-17. doi: 10.1111\/dme.12159.","journal-title":"Diabet Med"},{"issue":"4","key":"key20241021171135_B24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/dme.13588","article-title":"Diabetes technology: improving care, improving patient-reported outcomes and preventing complications in young people with type 1 diabetes","volume":"35","author":"Prahalad","year":"2018","unstructured":"24. Prahalad P, Tanenbaum M, Hood K, Maahs DM. Diabetes technology: improving care, improving patient-reported outcomes and preventing complications in young people with type 1 diabetes. Diabet Med. 2018;35(4):419-29. doi: 10.1111\/dme.13588.","journal-title":"Diabet Med"},{"issue":"7","key":"key20241021171135_B25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-128-7-199804010-00001","article-title":"Effect of Intensive Therapy on Residual Beta-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial. A Randomized, Controlled Trial. The Diabetes Control and Complications Trial Research Group","volume":"128","year":"1998","unstructured":"25. Effect of Intensive Therapy on Residual Beta-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications Trial. A Randomized, Controlled Trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med. 1998;128(7):517-23. doi: 10.7326\/0003-4819-128-7-199804010-00001.","journal-title":"Ann Intern Med"},{"issue":"10205","key":"key20241021171135_B26","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0140-6736(19)32127-0","article-title":"Changing the landscape for type 1 diabetes: the first step to prevention","volume":"394","author":"Dayan","year":"2019","unstructured":"26. Dayan CM, Korah M, Tatovic D, Bundy BN, Herold KC. Changing the landscape for type 1 diabetes: the first step to prevention. Lancet. 2019;394(10205):1286-96. doi: 10.1016\/S0140-6736(19)32127-0.","journal-title":"Lancet"}],"container-title":["Archives of Endocrinology and Metabolism"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T17:11:50Z","timestamp":1729530710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aem-sbem.com\/article\/metabolic-impact-of-residual-c-peptide-secretion-in-type-1-diabetes-mellitus\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":26,"alternative-id":["10.20945\/2359-4292-2023-0503"],"URL":"https:\/\/doi.org\/10.20945\/2359-4292-2023-0503","relation":{},"ISSN":["2359-3997","2359-4292"],"issn-type":[{"value":"2359-3997","type":"print"},{"value":"2359-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e230503"}}